|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | 0.00% |
|
0.00% | - |
| 18-11-13 | CaliPharms, Inc. Launches a New CBD Muscle & Joint Relief Roll On Gel | CI |
| 18-08-30 | Joe Pavlik Joins the Advisory Board of CaliPharms, Inc | CI |
| Market Cap | 401K 352K 324K 300K 568K 38.27M 577K 3.87M 1.52M 18.85M 1.51M 1.47M 64.88M | P/E 2012 * |
-
| P/E 2013 | -0.51x |
|---|---|---|---|---|---|
| Enterprise Value | 1.07M 936K 863K 797K 1.51M 102M 1.54M 10.31M 4.04M 50.17M 4.01M 3.92M 173M | EV / Sales 2012 * |
-
| EV / Sales 2013 | - |
| Free-Float |
100% | Yield 2012 * |
-
| Yield 2013 | - |
| 1 year | 0 | 0 | |
| 3 years | 0 | 0 | |
| 5 years | 0 | 0 | |
| 10 years | 0 | 0.01 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | - | - | 13.88K | ||
| +0.95% | -0.08% | -12.82% | -8.16% | 12.7B | ||
| +2.42% | +1.37% | -33.43% | -54.80% | 4.67B | ||
| -0.02% | -0.64% | -6.89% | -5.76% | 4.4B | ||
| -7.84% | -7.31% | +12.48% | -9.74% | 3.92B | ||
| +2.11% | -0.70% | +4.02% | -37.69% | 3.73B | ||
| -0.58% | +6.63% | -8.69% | -13.03% | 3.27B | ||
| +0.28% | +0.57% | -11.39% | +2.92% | 3.09B | ||
| -0.77% | +1.24% | -7.85% | -23.20% | 2.42B | ||
| -0.32% | +4.78% | -5.40% | +44.70% | 1.81B | ||
| Average | -0.38% | -1.02% | -7.77% | -11.64% | 4B | |
| Weighted average by Cap. | -0.08% | -1.30% | -9.44% | -14.32% |
| 2012 | 2013 | |
|---|---|---|
| Net sales | - | - |
| Net income | -917K -803K -741K -684K -1.3M -87.44M -1.32M -8.85M -3.47M -43.07M -3.44M -3.37M -148M | -216K -190K -175K -162K -306K -20.64M -311K -2.09M -819K -10.17M -813K -795K -35M |
| Net Debt | 617K 540K 498K 460K 873K 58.81M 887K 5.95M 2.33M 28.97M 2.32M 2.26M 99.7M | 667K 584K 539K 498K 943K 63.58M 959K 6.43M 2.52M 31.32M 2.5M 2.45M 108M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
- Stock Market
- Stocks
- KGET Stock
Select your edition
All financial news and data tailored to specific country editions
















